Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLP2A-alendronate
- Development stage
- Phase 2
- Lead developer
- Regenerative Arthritis and Bone Medicine
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
**LLP2A-alendronate** is an investigational bone-targeting peptide-drug conjugate that covalently links LLP2A, a peptidomimetic ligand for activated integrin alpha-4/beta-1 on mesenchymal stem cells, to the bone-seeking bisphosphonate alendronate. The conjugate is designed to recruit endogenous or transplanted mesenchymal stem cells to bone surfaces, where they can differentiate toward osteoblasts and enhance bone formation and repair. It originated at the University of California, Davis and was licensed to RABOME; development has included an intravenous Phase 1 study in glucocorticoid-associated osteopenia and a Phase 2 study of RAB001 in steroid-induced early-stage osteonecrosis of the femoral head. ([research.ucdavis.edu](https://research.ucdavis.edu/uc-davis-licenses-novel-compound-that-helps-stem-cells-regenerate-bone-to-treat-bone-diseases/))
- Other names
- LLP2A-AleLLP-2A-AleLLP 2A-Ale
02
Targets
α4β1 (Integrin α4β1)
Beyond the preview
Go deeper on LLP2A-alendronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLP2A-alendronate.